FDA panel to review GSK blood-clotting drug

WASHINGTON A Food and Drug Administration panel will meet at the end of the month to review a drug by GlaxoSmithKline that is designed to treat chronic immune thrombocytopenic purpura, according to Reuters.

The disease is a disorder in which the blood does not clot properly, which leads to a low number of platelets in the blood which blocks clotting.

The advisory committee will meet on May 30 in Chicago during the annual meeting of the American Society for Clinical Oncology.

GSK is in a race right now with Amgen to get approval for their ITP drug. Last month, the FDA delayed Amgen’s drug romiplastin decision for approval, so the agency could review more information about the drug.